Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazorra, Zaima, Lavastida, Anabel, Concha-Benavente, Fernando, Valdés, Anet, Srivastava, Raghvendra M., García-Bates, Tatiana M., Hechavarría, Esperanza, González, Zuyen, González, Amnely, Lugiollo, Martha, Cuevas, Iván, Frómeta, Carlos, Mestre, Braulio F., Barroso, Maria C., Crombet, Tania, Ferris, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474456/
https://www.ncbi.nlm.nih.gov/pubmed/28674498
http://dx.doi.org/10.3389/fphar.2017.00382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474456/
https://www.ncbi.nlm.nih.gov/pubmed/28674498
http://dx.doi.org/10.3389/fphar.2017.00382

Ejemplares similares